Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

20 evidence topics · 13 sources

Anti-VEGF monoclonal antibodies and antibody fragments2 evidence topics · 1 source
VEGF trap fusion proteins2 evidence topics · 1 source
Bispecific Anti-VEGF/Angiopoietin-2 antibodies2 evidence topics · 1 source
Anti-VEGF biosimilars3 evidence topics · 2 sources
Off-label compounded bevacizumab4 evidence topics · 3 sources
Photodynamic therapy and thermal laser photocoagulation2 evidence topics · 2 sources
Limitations of current therapies5 evidence topics · 5 sources